Skip to main content

Advertisement

SpringerLink
Log in

Characterization of therapy and costs for patients with uterine fibroids in Utah Medicaid

  • Original Article
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Objectives

To determine in an eligible Utah Medicaid population (1) medical and drug costs associated with treating uterine fibroids (UFs) and (2) the cost and incidence of hysterectomy complications.

Methods

Medical and drug cost analyses were based on data from 897 premenopausal patients with UFs included in the Utah Medicaid database from 1996 to 2004. UF-related medical and pharmacy costs were determined from first diagnosis of UFs until a related procedure or until estimated menopause. Outcomes for patients treated with a procedure (hysterectomy, myomectomy, or embolization), medication, and watchful waiting (no procedure, no UF-related drug) were compared. When determining hysterectomy complication rates for the population of women in the Medicaid database, a total of 1,323 pre- or postmenopausal patients with UFs were included.

Results

Overall, 20% of patients were treated with medication, 33% with a procedure, and 47% with watchful waiting. Mean total UF costs were: $11,996 (procedure), $2,703 (medication), and $2,118 (watchful waiting). Mean eligibility months were 8.8, 28.8, and 14.1, respectively. Costs/eligible month were: $1,358 (procedure), $151 (watchful waiting), and $94 (medication). The mean hysterectomy cost was $12,107.

Conclusion

Treatment for UFs is expensive with a mean cost of $5,504 per study patient. The highest costs are seen in patients receiving procedures, which can lead to complications; 15% in this study. Costs for watchful waiting are similar to costs in patients receiving UF-related drugs. Consideration should be given to using non-surgical therapies for the treatment of UFs before procedures are performed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Becker ER, Spalding J, DuChane J, Jorowitz IR (2005) Inpatient surgical treatment patterns for patients with uterine fibroids in the United States, 1998–2002. J Natl Med Assoc 97(10):1336–1342

    PubMed  Google Scholar 

  2. Broder M (2002) Uterine fibroids. In: Pregler JP, DeCherney AH (eds) Women’s health: principles and practice. BC Decker Inc., Ontario

    Google Scholar 

  3. Broder MS (2004) Gynecologic procedures. In: Hacker N, Moore JG, Gambone JG (eds) Essentials of gynecology, 4th edn. WB Saunders, New York

    Google Scholar 

  4. Broder MS, Spalding J (2006) Treatment patterns for women with new episodes of uterine myomas in an insured population in the US. Curr Med Res Opin 22:95–100

    Article  PubMed  Google Scholar 

  5. Carlson KJ, Miller BA, Fowler FJ Jr (1994) The Maine women’s health study: I. Outcomes of hysterectomy. Obstet Gynecol 83(4):556–565

    Article  PubMed  CAS  Google Scholar 

  6. Carlson KJ, Miller BA, Fowler FJ Jr (1994) The Maine women’s health study: II. Outcomes and nonsurgical management of leimyoma, abnormal bleeding, and chronic pelvic pain of hysterectomy. Obstet Gynecol 83(4):566–572

    PubMed  CAS  Google Scholar 

  7. Doridot V, Dubuisson JB, Chapron C, Fauconnier A, Babaki-Fard K (2001) Recurrence of leiomyomata after laparoscopic myomectomy. J Am Assoc Gynecol Laparosc 8(4):495–500

    Article  PubMed  CAS  Google Scholar 

  8. EMedicine Consumer Health—Menopause overview (accessed 10/05/04). http://www.emedicinehealth.com/articles/6759-1.asp

  9. Hakim RB, Benedict B, Merrick NJ (2004) Quality of care for women undergoing a hysterectomy: effects of insurance and race/ethnicity. Am J Public Health 94(8):1399–1405

    Article  PubMed  Google Scholar 

  10. Healthcare Cost and Utilization Project, AHRQ (accessed 2/5/06). http://hcup.ahrq.gov/HCUPnet.asp

  11. Kaiser Commission on Medicaid and the Uninsured (accessed 1/11/06). http://www.kff.org/medicaid/loader.cfm?url=/commonspot/security/getfile.cfm&PageID=33829

  12. Keshavarz H, Jikis SD, Kicke BA, Marchbanks PA; Centers for Disease Control and Prevention (2002) Hysterectomy surveillance—United States, 1994–1999. MMWR 51(SS05):1–8

  13. Kjerulff K, Langenberg P, Guzinski G (1993) The socioeconomic correlates of hysterectomies in the United States. Am J Public Health 83(1):106–108

    PubMed  CAS  Google Scholar 

  14. Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE, Colditz GA et al (1997) Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 90(6):967–973

    Article  PubMed  CAS  Google Scholar 

  15. National Pharmaceutical Council (2003) Pharmaceutical benefits under State Medical Assistance Programs. National Pharmaceutical Council Inc., Reston

  16. National Uterine Fibroids Association (accessed 12/16/05). www.nuff.org/health.htm

  17. Reuters Health (accessed 11/22/05). Uterine fibroids and hysterectomy, March 2002. http://www.reutershealth.com/wellconnected/doc73.html

  18. Rowe MK, Kanouse DE, Mittman BS, Bernstein SJ (1993) Quality of life among women undergoing hysterectomies. Obstet Gynecol 93(6):915–921

    Article  Google Scholar 

  19. Society of Interventional Radiology (accessed 11/22/05). Uterine fibroid treatment options. http://www.sirweb.org/patPub/uterineTreatments.html

  20. Van Noord PAH et al (1997) Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors. Fertil Steril 14:95–102

    Article  Google Scholar 

Download references

Acknowledgment

This project was funded by TAP Pharmaceutical Products Inc.

Author information

Authors and Affiliations

  1. Department of Pharmacotherapy, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, 421 Wakara Way, Suite 208, Salt Lake City, UT, 84108, USA

    Gary Oderda & Carl Asche

  2. Department of Obstetrics and Gynecology, School of Medicine, 30 N 1900 E Rm 2B200, Salt Lake City, UT, 84112, USA

    Kirtly Parker Jones

  3. Department of Health Science, Brigham Young University, 229-A Richards Building, Provo, UT, 84602, USA

    Ray M. Merrill

  4. Health Economics and Outcomes Research, Medical Affairs, TAP Pharmaceutical Products Inc., 675 N. Field Drive, Lake Forest, IL, 60045, USA

    James Spalding

Authors
  1. Gary Oderda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carl Asche
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kirtly Parker Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ray M. Merrill
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. James Spalding
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gary Oderda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oderda, G., Asche, C., Jones, K.P. et al. Characterization of therapy and costs for patients with uterine fibroids in Utah Medicaid. Arch Gynecol Obstet 276, 211–218 (2007). https://doi.org/10.1007/s00404-007-0332-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-007-0332-6

Keywords

Search

Navigation